GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OSTO:CEVI) » Definitions » EV-to-Revenue

CellaVision AB (OSTO:CEVI) EV-to-Revenue : 5.65 (As of May. 25, 2025)


View and export this data going back to 2007. Start your Free Trial

What is CellaVision AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CellaVision AB's enterprise value is kr4,229.3 Mil. CellaVision AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr747.9 Mil. Therefore, CellaVision AB's EV-to-Revenue for today is 5.65.

The historical rank and industry rank for CellaVision AB's EV-to-Revenue or its related term are showing as below:

OSTO:CEVI' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.95   Med: 11.19   Max: 22.75
Current: 5.65

During the past 13 years, the highest EV-to-Revenue of CellaVision AB was 22.75. The lowest was 3.95. And the median was 11.19.

OSTO:CEVI's EV-to-Revenue is ranked worse than
68.33% of 821 companies
in the Medical Devices & Instruments industry
Industry Median: 3.11 vs OSTO:CEVI: 5.65

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-25), CellaVision AB's stock price is kr184.00. CellaVision AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr31.36. Therefore, CellaVision AB's PS Ratio for today is 5.87.


CellaVision AB EV-to-Revenue Historical Data

The historical data trend for CellaVision AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB EV-to-Revenue Chart

CellaVision AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.60 13.73 8.53 7.38 7.00

CellaVision AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.89 8.12 9.34 7.00 5.11

Competitive Comparison of CellaVision AB's EV-to-Revenue

For the Medical Devices subindustry, CellaVision AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CellaVision AB's EV-to-Revenue falls into.


;
;

CellaVision AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CellaVision AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4229.325/747.939
=5.65

CellaVision AB's current Enterprise Value is kr4,229.3 Mil.
CellaVision AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr747.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB  (OSTO:CEVI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CellaVision AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=184.00/31.357
=5.87

CellaVision AB's share price for today is kr184.00.
CellaVision AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr31.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CellaVision AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.

CellaVision AB Headlines

No Headlines